½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1441268

¼¼°èÀÇ ¾Ï ÁöÁö¿ä¹ý ¾àÁ¦ ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå ºÐ¼®, À¯Çüº°, ¿ëµµº°, »ê¾÷º° ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå ºÐ¼® - »ê¾÷ ¿¹Ãø(2023-2030³â)

Global Cancer Supportive Care Drugs Market Size, Share, Growth Analysis, By Type(ESA (Erythropoiesis-Stimulating Agents), G-CSFs (Granulocyte Colony-Stimulating Factors)), By Application(Breast Cancer, Lung Cancer) - Industry Forecast 2023-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: SkyQuest | ÆäÀÌÁö Á¤º¸: ¿µ¹® 157 Pages | ¹è¼Û¾È³» : 3-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¾Ï ÁöÁö¿ä¹ý ¾àÁ¦ ½ÃÀå ±Ô¸ð´Â 2022³â 883¾ï ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2023³â 942¾ï 2,000¸¸ ´Þ·¯¿¡¼­ 2031³â¿¡´Â 1,582¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÏ°í, ¿¹Ãø ±â°£(2024-2031³â) µ¿¾È 6.70%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°è ¾Ï º¸Á¶ Ä¡·áÁ¦ ½ÃÀåÀº ¾Ï Ä¡·áÀÇ ºÎÀÛ¿ëÀ» ¿ÏÈ­ÇÏ°í ¾Ï È¯ÀÚÀÇ Àü¹ÝÀûÀÎ »îÀÇ ÁúÀ» °³¼±ÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. È­Çпä¹ý, ¹æ»ç¼± Ä¡·á, Ç¥Àû Ä¡·á¿Í °°Àº Ä¡·á¹ýÀº Á¾Á¾ ºÎÀÛ¿ëÀ» À¯¹ßÇÏ´Â °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ º¸Á¶¿ä¹ýÁ¦´Â Áõ»ó °ü¸®¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ ½ÃÀåÀº ¾Ï ¹ßº´·ü Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡, ¾Ï Ä¡·á¹ýÀÇ ¹ßÀü µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ Å©°Ô ¼ºÀåÇÏ°í ÀÖ½À´Ï´Ù. ÁöÁö¿ä¹ýÀº ±¸ÅäÁ¦, ÁøÅëÁ¦, Á¶Ç÷Á¦ µî ´Ù¾çÇÑ ÀǾàÇ°À» Æ÷ÇÔÇϸç, Ä¡·áÀÇ ºÎÀÛ¿ëÀ» ÁÙÀ̱â À§ÇÑ ¸ñÀûÀ¸·Î »ç¿ëµË´Ï´Ù. Áö¼ÓÀûÀÎ ¿¬±¸ °³¹ß ³ë·ÂÀº º¸´Ù Á¤È®ÇÏ°í È¿°úÀûÀÎ ÁöÁö¿ä¹ýÀ» °³¹ßÇϱâ À§ÇØ ÁýÁߵǰí ÀÖ½À´Ï´Ù. Á¦¾àȸ»çµéÀº ¾Ï Ä¡·á¿Í ÁöÁö¿ä¹ýÀ» ÅëÇÕÇÑ Á¾ÇÕÀûÀÎ Ä¡·á ¿É¼ÇÀ» Á¦°øÇϱâ À§ÇØ Çù·ÂÇÏ°í ÀÖ½À´Ï´Ù. ¾Ï Ä¡·á¹ýÀÌ ¹ßÀüÇÔ¿¡ µû¶ó ÁöÁö¿ä¹ý ¾à¹°¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î´Â ȯÀÚ Áß½ÉÀÇ Á¢±Ù ¹æ½Ä°ú Ä¡·á Áß È¯ÀÚÀÇ °Ç°­ À¯ÁöÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö´Â °ÍÀ» µé ¼ö ÀÖ½À´Ï´Ù. Ä¡·á¿Í °ü·ÃµÈ ºÎÀÛ¿ëÀ» Ç¥ÀûÀ¸·Î »ï°í ȯÀÚÀÇ Æí¾ÈÇÔÀ» Çâ»ó½ÃÅ°´Â Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ °³¹ßÀº ¼¼°è ¾Ï º¸Á¶¿ä¹ý ½ÃÀåÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¸ñÂ÷

ÁÖ¿ä ¿ä¾à

  • ½ÃÀå °³¿ä
  • ¹ø¿µ°ú ¼èÅð

Á¶»ç ¹æ¹ý

  • Á¤º¸ Á¶´Þ
  • 2Â÷/1Â÷ Á¤º¸¿ø
  • ½ÃÀå ±Ô¸ð ÃßÁ¤
  • ½ÃÀå ÀüÁ¦Á¶°Ç°ú Á¦ÇÑ

»óÀ§ ½ÃÀå ºÐ¼®

  • ½ÃÀå °³¿ä
  • ½ÃÀå ±Ô¸ð
  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ±âȸ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • °úÁ¦

ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®

  • ±â¼ú ºÐ¼®
  • °¡°Ý ºÐ¼®
  • °ø±Þ¸Á ºÐ¼®
  • ¹ë·ùüÀÎ ºÐ¼®
  • ½ÃÀå »ýÅ°è
  • IP ºÐ¼®
  • ¹«¿ª ºÐ¼®
  • ½ºÅ¸Æ®¾÷ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
  • Çõ½Å ¸ÅÆ®¸¯½º
  • ÆÄÀÌÇÁ¶óÀÎ Á¦Ç° ºÐ¼®
  • °Å½Ã°æÁ¦ ÁöÇ¥
  • ÁÖ¿ä ÅõÀÚ ºÐ¼®
  • ÁÖ¿ä ¼º°ø ¿äÀÎ
  • °æÀï Á¤µµ

½ÃÀå ¿ªÇаú Àü¸Á

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ±âȸ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • °úÁ¦
  • ±ÔÁ¦ »óȲ
  • PorterÀÇ Five Forces ºÐ¼®
  • ÇâÈÄ È¥¶õ¿¡ °üÇÑ Æ¯º° ÀλçÀÌÆ®

¼¼°èÀÇ ¾Ï ÁöÁö¿ä¹ý ¾àÁ¦ ½ÃÀå : À¯Çüº°

  • ½ÃÀå °³¿ä
  • ESA (Erythropoiesis-Stimulating Agents)
  • G-CSFs (Granulocyte Colony-Stimulating Factors)
  • Ç×±¸ÅäÁ¦
  • ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ®
  • ¿ÀÇÇ¿ÀÀ̵å
  • NSAIDs (Non-Steroidal Auto Inflammatory Drugs)
  • ±âŸ

¼¼°èÀÇ ¾Ï ÁöÁö¿ä¹ý ¾àÁ¦ ½ÃÀå : ¿ëµµº°

  • ½ÃÀå °³¿ä
  • À¯¹æ¾Ï
  • Æó¾Ï
  • °áÀåÁ÷Àå¾Ï
  • Àü¸³¼±¾Ï
  • °£¾Ï
  • À§¾Ï
  • ±âŸ

¼¼°èÀÇ ¾Ï ÁöÁö¿ä¹ý ¾àÁ¦ ½ÃÀå ±Ô¸ð : Áö¿ªº°

  • ½ÃÀå °³¿ä
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ½ºÆäÀÎ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • GCC ±¹°¡
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

°æÀï ±¸µµ

  • ÁÖ¿ä 5°³»ç ºñ±³
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×(2021³â)
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÌ Ã¤ÅÃÇÑ Àü·«
  • ÁÖ¿ä ¼º°ø Àü·«
  • ½ÃÀå¿¡¼­ÀÇ ÃÖ±Ù È°µ¿
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À²(2021³â)

ÁÖ¿ä ±â¾÷ °³¿ä

  • Amgen Inc.(¹Ì±¹)
  • Johnson & Johnson(¹Ì±¹)
  • Roche Holding AG(½ºÀ§½º)
  • Amneal Pharmaceuticals LLC(¹Ì±¹)
  • Novartis AG(½ºÀ§½º)
  • Pfizer Inc.(¹Ì±¹)
  • Mylan N.V.(¹Ì±¹)
  • Bristol Myers Squibb(¹Ì±¹)
  • Merck & Co., Inc.(¹Ì±¹)
  • Ipsen Pharma(ÇÁ¶û½º)
  • Eli Lilly and Company(¹Ì±¹)
  • Teva Pharmaceutical Industries Ltd.(À̽º¶ó¿¤)
  • Helsinn Healthcare SA(½ºÀ§½º)
  • GlaxoSmithKline plc(¿µ±¹)
  • F. Hoffmann-La Roche Ltd.(½ºÀ§½º)
  • Takeda Pharmaceutical Company Limited(ÀϺ»)
  • Eisai Co., Ltd.(ÀϺ»)
  • Astellas Pharma Inc.(ÀϺ»)
  • Mundipharma International Limited(¿µ±¹)
  • Sanofi(ÇÁ¶û½º)
  • Bayer AG(µ¶ÀÏ)
  • AstraZeneca plc(¿µ±¹)
  • Kyowa Kirin Co., Ltd.(ÀϺ»)
  • Dr. Reddy's Laboratories Ltd.(Àεµ)
  • Sun Pharmaceutical Industries Ltd.(Àεµ)
LSH 24.04.11

Global Cancer Supportive Care Drugs Market size was valued at USD 88.3 billion in 2022 and is poised to grow from USD 94.22 billion in 2023 to USD 158.29 billion by 2031, growing at a CAGR of 6.70% during the forecast period (2024-2031).

The global market for cancer supportive care drugs is instrumental in alleviating the adverse effects of cancer treatments and improving the overall quality of life for cancer patients. Therapies like chemotherapy, radiation, and targeted treatments often bring about debilitating side effects, making supportive care drugs indispensable for symptom management. This market has experienced substantial expansion driven by factors such as rising cancer prevalence, a growing elderly population, and advancements in cancer therapies. Supportive care drugs encompass a diverse range of pharmaceuticals, including antiemetics, analgesics, hematopoietic agents, among others, aiming to mitigate treatment side effects. Continuous research and development efforts are focused on creating more precise and efficacious supportive care therapies. Pharmaceutical companies are collaborating to offer comprehensive treatment options integrating cancer therapies with supportive care drugs. Anticipated advancements in cancer treatment methods are expected to further drive the demand for supportive care drugs. Key drivers of the market's growth include a patient-centric approach and increased awareness of the importance of maintaining patient well-being during treatment. The ongoing development of innovative therapies targeting treatment-related side effects and enhancing patient comfort will play a pivotal role in shaping the future landscape of the global cancer supportive care drugs market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Supportive Care Drugs Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Supportive Care Drugs Market Segmental Analysis

By Type, the market is segmented into ESA (Erythropoiesis-Stimulating Agents), G-CSFs (Granulocyte Colony-Stimulating Factors), Antiemetics, Bisphosphonates, Opioids, NSAIDs (Non-Steroidal Auto Inflammatory Drugs), Others. By Application, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, Stomach Cancer, Others. By distribution channel, the market is segmented into Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Cancer Supportive Care Drugs Market

The escalating worldwide incidence of cancer underscores the growing necessity for cancer supportive care medications. As more individuals undergo treatments such as chemotherapy, radiation therapy, and targeted therapies, the demand intensifies for managing the adverse effects associated with these interventions. Supportive care drugs play a crucial role in enhancing patients' quality of life by alleviating symptoms such as nausea, pain, anemia, and fatigue, thereby providing significant relief throughout their cancer treatment journey.

Restraints in the Global Cancer Supportive Care Drugs Market

The complex process of approving cancer supportive drugs stems from the necessity for rigorous clinical trials to ascertain their safety and efficacy. This intricate approval procedure, governed by regulatory barriers and stringent development and marketing guidelines, often leads to delays in introducing new medications to the market. Consequently, patients encounter challenges accessing innovative supportive care options, thereby limiting their treatment choices.

Market Trends of the Global Cancer Supportive Care Drugs Market

With the evolving landscape of cancer treatments tailored to individual patients, there's a growing recognition of the importance of personalized supportive care. This approach acknowledges the unique characteristics of each patient's cancer type, treatment regimen, and health status, leading to the development of specialized drugs to mitigate specific side effects and symptoms such as chemotherapy-induced nausea, vomiting, fatigue, and anemia. By enhancing the quality of life for patients and promoting treatment adherence, personalized supportive care not only addresses the challenges of cancer treatment but also enhances overall outcomes.

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Cancer Supportive Care Drugs Market by Type

  • Market Overview
  • ESA (Erythropoiesis-Stimulating Agents)
  • G-CSFs (Granulocyte Colony-Stimulating Factors)
  • Antiemetics
  • Bisphosphonates
  • Opioids
  • NSAIDs (Non-Steroidal Auto Inflammatory Drugs)
  • and Others

Global Cancer Supportive Care Drugs Market by Application

  • Market Overview
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Liver Cancer
  • Stomach Cancer
  • and Others

Global Cancer Supportive Care Drugs Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021

Key Company Profiles

  • Amgen Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Roche Holding AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amneal Pharmaceuticals LLC (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mylan N.V. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol Myers Squibb (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ipsen Pharma (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries Ltd. (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Helsinn Healthcare SA (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • F. Hoffmann-La Roche Ltd. (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eisai Co., Ltd. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Astellas Pharma Inc. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mundipharma International Limited (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kyowa Kirin Co., Ltd. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Dr. Reddy's Laboratories Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sun Pharmaceutical Industries Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦